June 10, 2021
Eisai CEO Haruo Naito While a yearly cost of US$56,000 is stirring another debate for Biogen’s Alzheimer’s drug Aduhelm (aducanumab), Haruo Naito, CEO of development partner Eisai, stressed the importance of value-based pricing on June 9 for therapies that improve...read more